Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$17.02
▼ $0.02 (-0.1%)
Market data updated: 09/20 07:48 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$883.66M
Day Range
$17.02 - $17.05
52-Week Range
$13.08 - $21.03
Beta
—
Next Earnings
09.11.2026
Support
$16.80
Resistance
$17.25
TBPH is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+17.6% (1Y)
Strengths: 15/25 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 66.9%
Growth
Biggest negative driver
Operating margin
Operating margin: -3.4% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
59
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
74
Quality
58
Value
55
Momentum
44
Risk
64
Sentiment
74
Fundamental
61
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Theravance Biopharma, Inc. has centered on its **Q2 2026 financial performance**, where the company reported a **net loss** despite beating adjusted earnings-per-share (EPS) estimates ($0.18 vs. $0.05 expected) and a **missed revenue target** ($20.731M vs. $21.6M forecast). Notably, the company is also in **advanced acquisition talks with Zymeworks**, as per Zacks, signaling a potential strategic shift. The focus remains on financial struggles amid positive earnings surprises.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Theravance Biopharma, Inc.. News trend score: 74. Reason: 6 of the last 18 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
9
🎯 Conviction (vs. Emotion)
45
Psychology
74
Fundamentals
61
Technical
44
Valuation
55
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+3%
Market Narrative
54
Fundamental Reality
45
Narrative Gap
+9
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant anchoring bias (77) reflects traders’ fixation on the 1.1% resistance gap, despite modest momentum and neutral sentiment. Herding (44) hints at passive peer alignment, while FOMO (24) remains muted by lack of extreme volatility or euphoric indicators. The narrative gap (7) suggests a slight disconnect between market perception and fundamentals, but no clear catalyst emerges. The key question: will traders break resistance or retreat if momentum stalls?
Updated: 09/09/2026, 09:18 AM
What could change this?
👥 What the crowd believes
"reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent"
"Theravance Biopharma Swings to Net Loss in Q2, Revenue Falls"
"Theravance Biopharma Insider Sold Shares Worth $5,791,555"
📈 14D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Jack Schwager — 46/100
🗣️ Why do they disagree?
The methodologies here split sharply between bullish and cautious camps, reflecting starkly different priorities. At the top, Bagehot, Housel, and Lynch all score near-perfectly, praising the stock’s liquidity, patient-holding potential, and undervalued growth—suggesting a consensus among value-oriented and growth-minded investors that this stock aligns with their core principles. Meanwhile, Fisher’s high score reinforces the idea of strong fundamentals, while Loeb and Livermore’s mid-range scores hint at a balance of stability and momentum. On the other end, Graham (both defensive and enterprising), Marks (market-cycle), and Nelson all flag concerns: Graham sees it as a borderline case, Marks warns of late-cycle risks, and Nelson’s low score signals overbought conditions. The divide underscores whether the stock’s growth or liquidity justifies its valuation—or if it’s already priced for perfection, leaving room for contrarian or cycle-sensitive investors to question its near-term appeal.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 100
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 96
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 93
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 82
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 78
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 78
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 71
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 67
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 64
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 63
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 57
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 49
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 47
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (4 bullish · 7 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a trading range, but the picture isn't yet clear enough on the likely direction.
Low confidence
$16.80
Range Bottom
$17.25
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-3.4%
Net Margin
98.5%
EBITDA Margin
-3.4%
ROE
35.7%
ROA
21.8%
ROIC
—
EPS
$2.10
Cash
$167.81M
Total Debt
—
Current Ratio
10.93
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$5.76
Tangible Book Value per Share (Tangible NAV)
$5.76
Sentiment based on basic keywords (not AI) — 6 positive, 10 neutral, 2 negative out of the last 18 articles.
SeekingAlpha · 18.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
Zacks · 11.8.2026
MT Newswires · 10.8.2026
Associated Press · 10.8.2026
PR Newswire · 10.8.2026
Benzinga · 10.8.2026
Zacks · 6.8.2026
GlobeNewswire · 6.8.2026
Zacks · 3.8.2026
Zacks · 30.7.2026
GlobeNewswire · 16.7.2026
MT Newswires · 2.7.2026
Simply Wall St. · 1.7.2026
Zacks · 30.6.2026
Pharmaceutical Technology · 30.6.2026
MT Newswires · 29.6.2026
Theravance Biopharma, Inc. (TBPH) currently has a StockIQ AI score of 59/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TBPH currently scores 59/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
TBPH's technical score is 44/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 66.9%; Earnings per share (EPS) growth: 279.1%; Net income growth: 287.7%.
Based on the real signals StockIQ computed: Operating margin: -3.4% (negative); Price is below the 200-day average; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for TBPH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 13 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Miller Aine | Tax Withholding in Shares | 20.8.2026 | 189,826 | -6,258 | $16.95 |
| Grimaud Brett A. | Tax Withholding in Shares | 20.8.2026 | 355,168 | -7,952 | $16.95 |
| Farnum Rhonda | Tax Withholding in Shares | 20.8.2026 | 226,790 | -5,667 | $16.95 |
| Winningham Rick E | Tax Withholding in Shares | 20.8.2026 | 1,611,022 | -20,034 | $16.95 |
| Sawaf Aziz | Tax Withholding in Shares | 20.8.2026 | 336,841 | -8,112 | $16.95 |
| Sawaf Aziz | Tax Withholding in Shares | 20.8.2026 | 8,112 | -8,112 | $16.95 |
| Farnum Rhonda | Tax Withholding in Shares | 20.8.2026 | 5,667 | -5,667 | $16.95 |
| Miller Aine | Tax Withholding in Shares | 20.8.2026 | 6,258 | -6,258 | $16.95 |
| Winningham Rick E | Tax Withholding in Shares | 20.8.2026 | 20,034 | -20,034 | $16.95 |
| Grimaud Brett A. | Tax Withholding in Shares | 20.8.2026 | 7,952 | -7,952 | $16.95 |
| Samaha Eli | Open Market Sale | 7.7.2026 | 9,167,489 | -5,564 | $17.17 |
| Samaha Eli | Open Market Sale | 6.7.2026 | 9,173,053 | -1,400 | $17.04 |
| Samaha Eli | Open Market Sale | 1.7.2026 | 37,799 | -37,799 | $17.00 |
| Samaha Eli | Open Market Sale | 1.7.2026 | 9,174,453 | -37,799 | $17.00 |
| Samaha Eli | Open Market Sale | 30.6.2026 | 25,027 | -25,027 | $17.13 |
| Samaha Eli | Open Market Sale | 30.6.2026 | 9,212,252 | -25,027 | $17.13 |
| Samaha Eli | Open Market Sale | 29.6.2026 | 273,871 | -273,871 | $17.23 |
| Samaha Eli | Open Market Sale | 29.6.2026 | 9,237,279 | -273,871 | $17.23 |
| Miller Aine | Grant/Award from Employer | 19.6.2026 | 18,750 | +18,750 | — |
| Miller Aine | Grant/Award from Employer | 19.6.2026 | 196,084 | +18,750 | — |
| Farnum Rhonda | Open Market Sale | 15.6.2026 | 3,328 | -3,328 | $16.38 |
| Farnum Rhonda | Open Market Sale | 15.6.2026 | 3,329 | -3,329 | $16.39 |
| Farnum Rhonda | Open Market Sale | 15.6.2026 | 6,657 | -6,657 | $16.39 |
| Farnum Rhonda | Open Market Sale | 15.6.2026 | 242,442 | -3,329 | $16.39 |
| Farnum Rhonda | Open Market Sale | 15.6.2026 | 239,114 | -3,328 | $16.38 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,618,508 shares short as of 2026-08-31 · vs. 4,168,511 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
49.6% of trading volume this week was short selling, vs. 56.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology